Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Effect of Citrate Dialysate on Vascular Calcification
Vascular Calcification
Primary: Length of Calcified Artery Segments — 47; 9 millimeters (mm) per year
N/A N=37 Sodium Thiosulfate Treatment of Vascular Calcification in ESRD
Complication of Hemodialysis · Cardiovascular Diseases
Primary: Change in Annualized Coronary Calcium Volume Score After Treatment With Sodium Thiosulfate. — 6.6 mm3/year — p=0.001
Phase 4 N=360 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Chronic Kidney Disease · End Stage Renal Disease · Coronary Artery Calcification
Primary: Percent Change From Baseline in CAC Score — 43.74; 57.39 Units on a scale — p=0.073
Phase 3 N=128 Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
Arterial Dysfunction · Chronic Kidney Disease
Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…
N/A N=41 Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
Chronic Kidney Disease
Primary: Change in Circulating ICAM-1 Shown by Absolute Values at Baseline, Day 28 and Day 56 — 707; 701; 679; 627 nanogram/ml — p=>0.05
N/A N=70 Warfarin and Coronary Calcification Project
Coronary Calcification
Primary: Coronary Calcification (Presence and Degree as Measured by Agatston Score) Attributed to Duration of Warfarin Use in Months After Controlling for Standard Cardiovascular…
Phase 4 N=24 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
Hyperparathyroidism, Secondary · Kidney Failure, Chronic
Primary: Change in Endothelial Cell Function — .23 percent change in FMD
Phase 4 N=66 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Atrial Fibrillation
Primary: Coronary Artery Calcium (CAC) Score — 66; 31 units on a scale
Phase 2 N=274 Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
Cardiovascular Diseases · Cardiovascular Abnormalities · Calcifications, Vascular
Primary: Change in Log CAC Volume Score From Baseline to Week 52 for the Combined Dose Groups vs Placebo — 1.11; 1.20 ratio
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
Phase 2 N=22 The Effect of Etelcalcetide on CKD-MBD
Chronic Kidney Disease Mineral and Bone Disorder · Renal Osteodystrophy · Vascular Calcification
Primary: Percent Change in PTH Levels — 0; -54.14; -64.04 percentage of change in PTH levels
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
N/A N=338 Vascular Risk After Kidney Transplantation
Cardiovascular Disease · Chronic Kidney Disease · Diabetes
Primary: Carotid Intima Media Thickness (CIMT) — 0.044 millimeters (mm)
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 2 N=18 A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
Phase 4 N=110 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Atherosclerosis
Primary: Coronary Artery Calcium (Serial Calcium Scans) — 26.3; 40.5 mm cubed
N/A N=225 Vitamin D and Vascular Health in Children
Obesity · Vitamin D Deficiency
Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88
N/A N=90 Vitamin D Replacement After Kidney Transplant
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Phase 4 N=55 The Jetstream G3™ Calcium Study
Peripheral Arterial Disease
Primary: Luminal Area Change — 5.1; 8.3 mm^2 — p=<0.0001
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
Phase 4 N=20 Effect of Atorvastatin on Bone-vascular Axis
Osteoporosis · Hypercholesterolemia
Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05
Phase 4 N=110 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36
N/A N=96 Vitamin D Repletion in Coronary Artery Disease
Vitamin D Deficiency · Coronary Artery Disease · Endothelial Dysfunction
Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index
Phase 4 N=120 Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Cardiorenal Syndrome · Chronic Allograft Nephropathy
Primary: CAD (Chronic Allograft Dysfunction) Degree — 1.24; 1.22; 1.43; 1.68 Scores on a Banff scale — p=<0.05
Phase 2 N=22 Metabolic Effects of Paricalcitol
Chronic Kidney Disease
Primary: Glucose Area Under the Curve (AUC) — 20817; 21139 mg*min/dL
N/A N=125 Vitamin D, Insulin Resistance, and Cardiovascular Disease
Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus
Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg
N/A N=130 Effect of Vitamin D3 on Vascular Function
Vitamin D Deficiency
Primary: Pulse Wave Velocity for Vascular Stiffness — 29.3; 27.6 m/s
Phase 2 N=7 Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
Arterial Calcification · CD73 Deficiency
Primary: Ankle-brachial Index at Rest at Pre-treatment, On-treatment and Post-treatment of Etidronate in Participants Diagnosed With ACDC — 0.5741; 0.5411; 0.5222; 0.5266 score…